share_log

Ardelyx | 8-K: Current report

Ardelyx | 8-K: Current report

Ardelyx | 8-K：重大事件
美股sec公告 ·  06/17 09:05
Moomoo AI 已提取核心信息
Ardelyx, Inc., a biopharmaceutical company, announced the approval of amendments and restatements to its equity and employee stock plans following its 2024 Annual Meeting of Stockholders on June 14, 2024. The Board of Directors initially approved the changes to the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan on April 29, 2024. These amendments, referred to as the A&R 2014 Equity Plan and the A&R ESPP respectively, were subsequently ratified by stockholders at the Annual Meeting. The meeting also saw the election of Class I director nominees, approval of executive compensation on an advisory basis, and ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The detailed proposals and voting outcomes are incorporated by reference from the Proxy Statement filed with the SEC on April 29, 2024, and supplemented on June 4, 2024.
Ardelyx, Inc., a biopharmaceutical company, announced the approval of amendments and restatements to its equity and employee stock plans following its 2024 Annual Meeting of Stockholders on June 14, 2024. The Board of Directors initially approved the changes to the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan on April 29, 2024. These amendments, referred to as the A&R 2014 Equity Plan and the A&R ESPP respectively, were subsequently ratified by stockholders at the Annual Meeting. The meeting also saw the election of Class I director nominees, approval of executive compensation on an advisory basis, and ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The detailed proposals and voting outcomes are incorporated by reference from the Proxy Statement filed with the SEC on April 29, 2024, and supplemented on June 4, 2024.
生物制药公司Ardelyx，Inc.宣布在2024年股东年会（2024年6月14日）后，对其股权和员工股票计划的修正和重申获得批准。董事会最初批准了2014年股权激励奖计划和2014年员工股票购买计划的更改（分别称为A&R 2014 Equity Plan和A&R ESPP）于2024年4月29日。这些修正案随后由股东在年会上批准。本次会议还通过了一类董事提名、对执行薪酬的顾问性批准以及核准安永会计师事务所作为截至2024年12月31日财年的独立注册会计师。详细的提案和投票结果从2024年4月29日提交给美国证券交易委员会的代理声明中引入，并于2024年6月4日予以补充。
生物制药公司Ardelyx，Inc.宣布在2024年股东年会（2024年6月14日）后，对其股权和员工股票计划的修正和重申获得批准。董事会最初批准了2014年股权激励奖计划和2014年员工股票购买计划的更改（分别称为A&R 2014 Equity Plan和A&R ESPP）于2024年4月29日。这些修正案随后由股东在年会上批准。本次会议还通过了一类董事提名、对执行薪酬的顾问性批准以及核准安永会计师事务所作为截至2024年12月31日财年的独立注册会计师。详细的提案和投票结果从2024年4月29日提交给美国证券交易委员会的代理声明中引入，并于2024年6月4日予以补充。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息